Loading...

Cassiopea

OTCPK:CPPS.F
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CPPS.F
OTCPK
CHF530M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. The last earnings update was 70 days ago. More info.


Add to Portfolio Compare Print
CPPS.F Share Price and Events
7 Day Returns
0%
OTCPK:CPPS.F
-2%
US Pharmaceuticals
0.8%
US Market
1 Year Returns
-
OTCPK:CPPS.F
8.3%
US Pharmaceuticals
5.9%
US Market
CPPS.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cassiopea (CPPS.F) 0% 0% - - - -
US Pharmaceuticals -2% -2.8% 2% 8.3% 8.9% 16.1%
US Market 0.8% 2.6% 10.6% 5.9% 37.7% 45.5%
1 Year Return vs Industry and Market
  • No trading data on CPPS.F.
  • No trading data on CPPS.F.
Price Volatility
CPPS.F
Industry
5yr Volatility vs Market

CPPS.F Value

 Is Cassiopea undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Cassiopea to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Cassiopea.

OTCPK:CPPS.F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.9%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:CPPS.F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 9%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.68
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.676 (1 + (1- 24%) (0%))
0.783
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 9.02%)
9.95%

Discounted Cash Flow Calculation for OTCPK:CPPS.F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Cassiopea is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:CPPS.F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 9.95%)
2019 -22.00 Analyst x1 -20.01
2020 -29.10 Analyst x1 -24.07
2021 2.80 Analyst x2 2.11
2022 135.80 Analyst x1 92.94
2023 342.00 Analyst x1 212.88
2024 551.57 Est @ 61.28% 312.27
2025 792.68 Est @ 43.71% 408.17
2026 1,041.73 Est @ 31.42% 487.89
2027 1,279.36 Est @ 22.81% 544.98
2028 1,494.13 Est @ 16.79% 578.89
Present value of next 10 years cash flows €2,596.02
OTCPK:CPPS.F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €1,494.13 × (1 + 2.73%) ÷ (9.95% – 2.73%)
€21,271.12
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €21,271.12 ÷ (1 + 9.95%)10
€8,241.30
OTCPK:CPPS.F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €2,596.02 + €8,241.30
€10,837.33
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €10,837.33 / 10.00
€1472.76
OTCPK:CPPS.F Discount to Share Price
Calculation Result
Exchange Rate EUR/CHF
(Reporting currency to currency of SWX:SKIN)
1.14
Value per Share
(CHF)
= Value per Share in EUR x Exchange Rate (EUR/CHF)
= €1083.73 x 1.14
CHF1235.28
Non-primary Listing Adjustment Factor 1 share in OTCPK:CPPS.F represents 0.73585x of SWX:SKIN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.73585x
Value per Share
(Listing Adjusted, USD)
= Value per Share (CHF) x Listing Adjustment Factor
= CHF 1,235.28 x 0.73585
$908.98
Value per share (USD) From above. $908.98
Current discount Discount to share price of $39.00
= -1 x ($39.00 - $908.98) / $908.98
95.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Cassiopea is available for.
Intrinsic value
>50%
Share price is $39 vs Future cash flow value of $908.98
Current Discount Checks
For Cassiopea to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Cassiopea's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Cassiopea's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cassiopea's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cassiopea's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:CPPS.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-1.27
SWX:SKIN Share Price ** SWX (2019-01-31) in CHF CHF53
SWX:SKIN Share Price converted to EUR reporting currency Exchange rate (CHF/ EUR) 0.877 €46.5
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.23x
United States of America Market PE Ratio Median Figure of 3,078 Publicly-Listed Companies 18.23x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cassiopea.

OTCPK:CPPS.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:SKIN Share Price ÷ EPS (both in EUR)

= 46.5 ÷ -1.27

-36.74x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cassiopea is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Cassiopea is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Cassiopea's expected growth come at a high price?
Raw Data
OTCPK:CPPS.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -36.74x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
58.9%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 23 Publicly-Listed Pharmaceuticals Companies 1.49x
United States of America Market PEG Ratio Median Figure of 2,108 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cassiopea, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cassiopea's assets?
Raw Data
OTCPK:CPPS.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €1.45
SWX:SKIN Share Price * SWX (2019-01-31) in CHF CHF53
SWX:SKIN Share Price converted to EUR reporting currency Exchange rate (CHF/ EUR) 0.877 €46.5
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 3.52x
United States of America Market PB Ratio Median Figure of 5,172 Publicly-Listed Companies 1.93x
OTCPK:CPPS.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:SKIN Share Price ÷ Book Value per Share (both in EUR)

= 46.5 ÷ 1.45

32.04x

* Primary Listing of Cassiopea.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cassiopea is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Cassiopea's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Cassiopea has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CPPS.F Future Performance

 How is Cassiopea expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
58.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cassiopea expected to grow at an attractive rate?
  • Cassiopea's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Cassiopea's earnings growth is expected to exceed the United States of America market average.
  • Cassiopea's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:CPPS.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:CPPS.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 58.9%
OTCPK:CPPS.F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 53.9%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 17.4%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.9%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:CPPS.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:CPPS.F Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 358 227 190 3
2022-12-31 222 79 68 3
2021-12-31 94 -5 2 4
2020-12-31 78 -18 -23 3
2019-12-31 0 -21 -19 3
OTCPK:CPPS.F Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -13 -13
2018-09-30 2 -13 -12
2018-06-30 4 -14 -11
2018-03-31 4 -14 -12
2017-12-31 4 -14 -14
2017-09-30 5 -14 -12
2017-06-30 6 -15 -10
2017-03-31 6 -15 -10
2016-12-31 6 -15 -9
2016-09-30 3 -14 -11
2016-06-30 -12 -13
2016-03-31 -9 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cassiopea's earnings are expected to grow significantly at over 20% yearly.
  • Cassiopea's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:CPPS.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Cassiopea Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CPPS.F Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 18.93 27.35 10.50 2.00
2022-12-31 6.80 10.86 4.15 3.00
2021-12-31 -0.54 1.97 -2.20 3.00
2020-12-31 -2.30 -1.70 -2.90 2.00
2019-12-31 -2.14 -2.10 -2.17 2.00
OTCPK:CPPS.F Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -1.27
2018-09-30 -1.19
2018-06-30 -1.11
2018-03-31 -1.24
2017-12-31 -1.37
2017-09-30 -1.20
2017-06-30 -1.03
2017-03-31 -0.99
2016-12-31 -0.95
2016-09-30 -1.13
2016-06-30 -1.31
2016-03-31 -1.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cassiopea will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cassiopea's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cassiopea has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CPPS.F Past Performance

  How has Cassiopea performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cassiopea's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cassiopea does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cassiopea's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cassiopea's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Cassiopea's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cassiopea Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:CPPS.F Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.92 -12.66 1.89 12.24
2018-09-30 2.37 -11.89 1.61 12.64
2018-06-30 3.82 -11.12 1.33 13.03
2018-03-31 3.82 -12.39 1.41 13.05
2017-12-31 3.82 -13.66 1.48 13.06
2017-09-30 4.85 -11.97 1.65 13.61
2017-06-30 5.88 -10.29 1.81 14.16
2017-03-31 5.88 -9.89 1.92 14.24
2016-12-31 5.88 -9.50 2.03 14.31
2016-09-30 2.94 -11.31 1.77 13.21
2016-06-30 -13.12 1.51 12.10
2016-03-31 -9.77 1.22 10.03
2015-12-31 -6.45 0.76 7.60
2015-09-30 -4.70 0.53 5.67
2015-06-30 -2.96 0.31 3.74
2015-03-31 -2.71 0.11 3.37
2014-12-31 -2.78 0.06 3.86
2013-12-31 -3.14 0.04 4.36
2012-12-31 18.72 9.69 0.16 4.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cassiopea has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cassiopea has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cassiopea improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cassiopea's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cassiopea has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CPPS.F Health

 How is Cassiopea's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cassiopea's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cassiopea is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cassiopea has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cassiopea's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Cassiopea has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cassiopea Company Filings, last reported 3 months ago.

OTCPK:CPPS.F Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 14.51 0.00 4.61
2018-09-30 14.51 0.00 4.61
2018-06-30 20.05 0.00 11.36
2018-03-31 20.05 0.00 11.36
2017-12-31 26.35 0.00 17.60
2017-09-30 26.35 0.00 17.60
2017-06-30 30.29 0.00 25.08
2017-03-31 30.29 0.00 25.08
2016-12-31 39.15 0.00 33.66
2016-09-30 39.15 0.00 33.66
2016-06-30 39.45 0.00 40.08
2016-03-31 39.45 0.00 40.08
2015-12-31 47.18 0.00 48.11
2015-09-30 47.18 0.00 48.11
2015-06-30 51.72 0.00 52.18
2015-03-31 2.71 0.00 0.53
2014-12-31 3.63 0.00 0.84
2013-12-31 6.40 0.00 5.92
2012-12-31 9.72 0.00 14.52
  • Cassiopea has no debt.
  • Cassiopea has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cassiopea has less than a year of cash runway based on current free cash flow.
  • Cassiopea has less than a year of cash runway if free cash flow continues to grow at historical rates of 10.8% each year.
X
Financial health checks
We assess Cassiopea's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cassiopea has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CPPS.F Dividends

 What is Cassiopea's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cassiopea dividends.
If you bought $2,000 of Cassiopea shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cassiopea's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cassiopea's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:CPPS.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.7%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2009 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:CPPS.F Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cassiopea has not reported any payouts.
  • Unable to verify if Cassiopea's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cassiopea's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cassiopea has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cassiopea's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cassiopea afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cassiopea has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CPPS.F Management

 What is the CEO of Cassiopea's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Diana Harbort
COMPENSATION €276,152
AGE 52
TENURE AS CEO 4.3 years
CEO Bio

Ms. Diana Harbort serves as the Chief Executive Officer of Cassiopea S.p.A. since 2015 and has been its Executive Director since May 2015. Ms. Harbort served as the Head of Corporate Development at Medicis From 2005 to 2012. She served as Executive Director of Business Development at Medicis from 2003 to 2005. Ms. Harbort served as Director Business Development at Medicis since 1998 until 2003. she had various functions at Abbot Laboratories starting as a production planning specialist from 1989 to 1998. Then as a marketing product manager and finally as business development manager in the Chemical and Agricultural Products division. She has been Executive Director of Cassiopea S.p.A. since May 2015. Ms. Harbort has an MBA from JL Kellogg Graduate School of Management, Northwestern University in 1998 and a BBA from University of Wisconsin.

CEO Compensation
  • Diana's compensation has been consistent with company performance over the past year.
  • Diana's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Cassiopea management team in years:

4.3
Average Tenure
60
Average Age
  • The tenure for the Cassiopea management team is about average.
Management Team

Diana Harbort

TITLE
CEO & Executive Director
COMPENSATION
€276K
AGE
52
TENURE
4.3 yrs

Chris Tanner

TITLE
CFO & Head of Investor Relations
AGE
67
TENURE
4.3 yrs

Marco Pasero

TITLE
Chief Operating Officer
AGE
52
TENURE
4.3 yrs

Luigi Moro

TITLE
Chief Scientific Officer
AGE
67

Alessandro Mazzetti

TITLE
Chief Medical Officer
AGE
66
TENURE
2.3 yrs

Marco Lecchi

TITLE
Finance Director
AGE
54
Board of Directors Tenure

Average tenure and age of the Cassiopea board of directors in years:

3.9
Average Tenure
55
Average Age
  • The tenure for the Cassiopea board of directors is about average.
Board of Directors

Jan de Vries

TITLE
Non-Executive Chairman
COMPENSATION
€72K
AGE
72
TENURE
3.9 yrs

Diana Harbort

TITLE
CEO & Executive Director
COMPENSATION
€276K
AGE
52
TENURE
3.9 yrs

Pierpaolo Guzzo

TITLE
Non-Executive Independent Director
COMPENSATION
€57K
AGE
55
TENURE
4 yrs

Øyvind Bjordal

TITLE
Non-Executive Independent Director
COMPENSATION
€57K
AGE
52
TENURE
3.9 yrs

James Leyden

TITLE
Member of Scientific Advisory Board
AGE
77

Diane Thiboutot

TITLE
Member of Scientific Advisory Board

Ken Washenik

TITLE
Member of Scientific Advisory Board

Andrea Zaenglein

TITLE
Member of Scientific Advisory Board

Maurizio Baldassarini

TITLE
Independent & Non Executive Director
COMPENSATION
€28K
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Cassiopea's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cassiopea has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CPPS.F News

Simply Wall St News

CPPS.F Company Info

Description

Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy.

Details
Name: Cassiopea S.p.A.
CPPS.F
Exchange: OTCPK
Founded: 2013
CHF522,682,446
10,000,000
Website: http://www.cassiopea.com
Address: Cassiopea S.p.A.
Via Cristoforo Colombo, 1,
Lainate,
Milan, 20020,
Italy
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX SKIN Registered Shares SIX Swiss Exchange CH CHF 01. Jul 2015
OTCPK CPPS.F Registered Shares Pink Sheets LLC US USD 01. Jul 2015
DB CSP Registered Shares Deutsche Boerse AG DE EUR 01. Jul 2015
LSE 0R8Y Registered Shares London Stock Exchange GB CHF 01. Jul 2015
BATS-CHIXE SKINZ Registered Shares BATS 'Chi-X Europe' GB CHF 01. Jul 2015
Number of employees
Current staff
Staff numbers
8
Cassiopea employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 00:51
End of day share price update: 2019/01/31 00:00
Last estimates confirmation: 2019/04/16
Last earnings filing: 2019/02/08
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.